PULM (Pulmatrix Corp) שולי רווח נקי

Pulmatrix, Inc. (PULM) is a macro-resilient biotech company developing inhalation therapies for the lungs regardless of economic cycles. An innovative drug delivery system in the US ensures production stability. Net profit margins on shipments visualize this effect, with the current value standing at 0.00. The company is currently restructuring its assets, shifting from development toward the licensing of its iSPERSE technology and the search for partners.
Pulmatrix Corp (PULM) - פילוחי מדדים ודוחות פיננסיים

Selecting stocks with a high margin of safety begins with analyzing the efficiency of revenue conversion into net income. This indicator measures the portion of income remaining after covering all operating expenses and interest. For Pulmatrix, Inc. (PULM), this metric is sensitive to logistic disruptions in reagent procurement and the complexities of international trials. Temporary dips may reflect one-time costs rather than a systemic crisis. The net margin dynamics clearly visualize these market fluctuations.